State Street Corp Sells 26,460 Shares of Axonics, Inc. (NASDAQ:AXNX)

State Street Corp trimmed its position in shares of Axonics, Inc. (NASDAQ:AXNX) by 2.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,184,492 shares of the company’s stock after selling 26,460 shares during the quarter. State Street Corp owned approximately 2.32% of Axonics worth $82,441,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Headlands Technologies LLC boosted its position in Axonics by 162.1% during the 2nd quarter. Headlands Technologies LLC now owns 2,928 shares of the company’s stock valued at $197,000 after acquiring an additional 1,811 shares in the last quarter. Murchinson Ltd. bought a new stake in Axonics during the 3rd quarter valued at approximately $209,000. Xponance Inc. boosted its position in Axonics by 7.5% during the 2nd quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after acquiring an additional 225 shares in the last quarter. Entropy Technologies LP bought a new stake in Axonics during the 3rd quarter valued at approximately $395,000. Finally, Mercer Global Advisors Inc. ADV boosted its position in Axonics by 12.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock valued at $469,000 after acquiring an additional 785 shares in the last quarter. 99.48% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO Kari Leigh Keese sold 2,961 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the transaction, the chief financial officer now directly owns 40,362 shares in the company, valued at $2,801,526.42. The trade was a 6.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.85% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Axonics has a consensus rating of “Hold” and a consensus target price of $71.00.

Axonics Stock Up 0.8 %

Shares of AXNX opened at $70.98 on Tuesday. The business’s 50 day moving average price is $70.61 and its 200-day moving average price is $69.13. Axonics, Inc. has a 52 week low of $55.09 and a 52 week high of $71.05. The stock has a market cap of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.